A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales
- 809 Downloads
People with severe asthma experience significant respiratory symptoms and suffer adverse effects of oral corticosteroids (OCS), including disturbed mood and physical symptoms. OCS impacts on health-related quality of life (HRQoL) have not been quantified. Asthma HRQoL scales are valid as outcome measures for patients requiring OCS only if they assess the deficits imposed by OCS.
The aim of this study was to compare the burden of disease and treatment in patients with severe asthma with items in eight asthma-specific HRQoL scales.
Twenty-three patients with severe asthma recruited from a severe asthma clinic were interviewed about the impact of their respiratory symptoms and the burden of their treatment. The domains from a thematic analysis of these interviews were compared with the items of eight asthma-specific HRQoL scales.
In addition to the burden caused by symptoms, ten domains of OCS impact on HRQoL were identified: depression, irritability, sleep, hunger, weight, skin, gastric, pain, disease anxiety, and medication anxiety. Some patients experienced substantial HRQoL deficits attributed to OCS. Although all HRQoL scales include some OCS-relevant items, all eight scales fail to adequately assess the several types of burden experienced by some patients while on OCS.
The burden of OCS in severe asthma is neglected in policy and practice because it is not assessed in outcome studies. Existing asthma HRQoL scales provide an overly positive estimation of HRQoL in patients with frequent exposure to OCS and underestimate the benefit of interventions that reduce OCS exposure. Changes to existing measurement procedures are needed.
KeywordsSevere asthma Difficult asthma Quality of life Treatment burden Assessment
We thank Joe Lanario for help with manuscript preparation, Margaret Hart for help with recruiting patients, and the patients themselves for giving their time. This research was supported by an unrestricted medical education grant from Novartis UK.
Conflict of interest
All authors have received financial support from Novartis UK in relation to the research reported in this study.
- 10.Reddel, H. K., Taylor, D. R., & Bateman, E. D. (2009). Official American Thoracic Society/European Respiratory Society Statement: Asthma control and exacerbations standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine, 180, 59–99.CrossRefPubMedGoogle Scholar
- 18.Castro, M., King, T. S., Kunselman, S. J., Cabana, M. D., Denlinger, L., Holguin, F., et al. (2014). Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: The VIDA randomized clinical trial. Journal of the American Medical Association, 311, 2083–2091.Google Scholar
- 20.Eberhart, N. K., Sherbourne, C. D., Edelen, M. O., Stucky, B. D., Sin, N. L., & Lara, M. (2013). Development of a measure of asthma-specific quality of life among adults. Quality of Life Research, 23, 837–848.Google Scholar
- 28.Pakhale, S., Wood-Dauphinee, S., Spahija, A., Collet, J. P., Maltais, F., Bernard, S., et al. (2012). Respiratory Network of the FRSQ. Validation of a new questionnaire with generic and disease-specific qualities: The McGill COPD Quality of Life Questionnaire. Canadian Respiratory Journal, 19, 367–372.PubMedCentralPubMedGoogle Scholar